國家衛生研究院 NHRI:Item 3990099045/10836
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 915750      線上人數 : 1265
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10836


    題名: Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon
    作者: Hubner, RA;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Siveke, JT;Braiteh, FS;de Jong, FA;Belanger, B;Walls, R;Mody, PD;von Hoff, DD;Wang-Gillam, A
    貢獻者: National Institute of Cancer Research
    摘要: Background: Elevated baseline neutrophil-to-lymphocyte ratio (NLR), a marker of subclinical inflammation, is associated with poor survival in several malignancies including mPDAC. Here we report the association of NLR with overall survival (OS) and progression-free survival (PFS) in a post-hoc analysis of the NAPOLI-1 trial (NCT01494506), that demonstrated improved survival with nal-IRI+5-FU/LV vs 5-FU/LV for treatment of mPDAC patients (pts) after disease progression following gemcitabine-based therapy. Methods: Pts treated with nal-IRI+5-FU/LV or 5-FU/LV and available baseline NLR data were included (data cutoff: Nov 16, 2015). OS and PFS were assessed in pts with high (>5) or low (≤5) baseline NLR in individual and pooled treatment arms. Results: Baseline NLR was available for 221 pts: 116/117 nal-IRI+ 5-FU/LV pts and 105/105 5-FU/LV pts. In the pooled treatment arms, pts with NLR≤5 had significantly better OS compared to pts with NLR >5 (6.2 vs 3.7 months, HR = 0.7, p = 0.02). Interestingly, this improvement in OS in pts with low vs high NLR was significant in the nal-IRI+5-FU/LV arm (8.4 vs 4.3 months, HR = 0.5, p=0.001); but not in the 5-FU/LV arm (4.8 vs 3.1 months, HR = 0.9, p=0.6). Similarly, PFS was significantly higher in pts with NLR≤5 vs NLR >5 in the pooled treatment arms (2.7 vs 1.4 months, HR = 0.7, p=0.05), and the nal-IRI+5-FU/LV arm (4.2 vs 1.4 months, HR = 0.5, p=0.002), but not the 5-FU/LV arm (1.5 vs 1.4 months, HR = 1.1, p=0.6). Conclusions: Data from these exploratory analyses are consistent with previous reports on the prognostic value of baseline NLR in mPDAC, and extend it to the post-gemcitabine setting. Median OS and PFS were improved in pts with low vs high baseline NLR in the nal-IRI+5-FU/LV arm but not in the 5-FU/LV arm. Clinical implications of these data remain to be determined.
    日期: 2017-09
    關聯: Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 741P.
    Link to: https://doi.org/10.1093/annonc/mdx369.124
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000411324001255
    顯示於類別:[陳立宗] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000411324001255.pdf73KbAdobe PDF218檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋